share_log

Pharmaniaga's Remedy Working As 1H Profit Jumps Six-Fold To RM30 Million

Pharmaniaga's Remedy Working As 1H Profit Jumps Six-Fold To RM30 Million

Pharmaniaga的药物效果显著,上半年利润增长六倍至3000万马来西亚令吉
Business Today ·  08/21 09:55

Pharmaniaga Berhad's financial results for the first half ended 30 June 2024 with Profit After Tax rising to RM30 million, up from RM5.1 million in the same period last year.

Pharmaniaga Berhad截至2024年6月30日结束的上半年财务业绩显示,税后利润上涨至3,000万令吉,较去年同期的510万令吉有所增长。

During the first half of FY2024, the group posted a 4.3% increase in revenue to RM1.8 billion compared with RM1.7 billion in the preceding year's corresponding period, due to improved customer demand in the concession and Indonesia segments. The Earnings Before Interest, Taxation, Depreciation And Amortisation (EBITDA) was RM97.8 million, up by 53.5% against the same half last year of RM63.7 million, while Profit Before Zakat and Taxation (PBT) soared by 172.8% to RM42.4 million from RM15.5 million.

在FY2024上半年,该集团营业收入增长4.3%,达到1.8亿马币,相比去年同期的1.7亿马币,这主要是由于特许经营和印度尼西亚业务的客户需求改善所致。利息、税项、折旧和摊销前利润(EBITDA)为9780万马币,比去年同期的6370万马币增长了53.5%,而税前利润(PBT)则猛增172.8%,从1550万马币增至4240万马币。

The results were driven primarily by the Group's cost optimisation initiatives that have contributed to the reduction of operating expenses by 11.1% during the first half year, against the same period in 2023.

这些成绩主要得益于该集团的成本优化措施,在上半年将营业费用减少了11.1%,这与2023年同期相比。

For the second quarter of FY2024, Pharmaniaga posted RM3.8 million PAT higher by 65.5% compared with RM2.3 million in the same quarter last year. Meanwhile, the Group recorded a lower PBT of RM3.3 million, against RM6.3 million in the corresponding quarter of 2023, mainly due to higher finance cost resulting from increased borrowings. The Group also registered RM838.3 million in revenue, 1.2% lower compared with RM848.7 million in the same quarter last year, while EBITDA recorded a 0.2% increase to RM31.3 million, from RM31.2 million.

在FY2024第二季度,Pharmaniaga的纯利润达到380万马币,较去年同季度的230万马币增长了65.5%。与此同时,该集团的税前利润则降至330万马币,与2023年同期的630万马币相比,这主要是由于借款增加导致的财务成本增加。该集团的营业收入为83830万马币,较去年同季度的84870万马币下降1.2%,而EBITDA则增长了0.2%,达到3130万马币,而原来是3120万马币。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发